Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
1,082 ^USD	-1.63%		+2.84%	+23.21%

07-12	UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating	MT
07-11	Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183	MT

Regeneron Pharmaceuticals : Exec Says Its Antibody Cocktail Therapy For COVID-19 Will Likely Help Against Variants Of The Virus - J.P.Morgan Conf

January 11, 2021 at 11:51 am

Jan 11 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON EXECUTIVE SAYS ITS ANTIBODY COCKTAIL THERAPY AGAINST COVID-19 WILL LIKELY HELP AGAINST VARIANTS OF THE VIRUS - J.P.MORGAN CONF

* REGENERON EXECUTIVE SAYS CO WORKING WITH U.S. GOVERNMENT TO RECTIFY PROBLEMS WITH ACCESS TO ITS ANTIBODY THERAPY FOR COVID-19 - J.P.MORGAN CONF

* REGENERON EXECUTIVE SAYS CO DEVELOPING ADDITIONAL ANTIBODY COCKTAIL THERAPIES AGAINST COVID-19 SHOULD THE VIRUS CONTINUE TO MUTATE - J.P.MORGAN CONF Further company coverage:

Latest news about Regeneron Pharmaceuticals, Inc.

UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating	07-12	MT
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183	07-11	MT
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050	07-10	MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating	07-09	MT
Regeneron Expects Earnings Hit After $24 Million R&D Charge	07-08	DJ
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval	07-03	MT
Sanofi obtains EU approval for Dupixent	07-03	RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease	07-03	DJ
EU approves Sanofi's Dupixent for 'smoker's lungs'	07-03	RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD	07-03	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing	07-02	MT
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Dynamic Index	06-30	CI
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab	06-28	MT
Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab	06-28	DJ
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	06-28	CI
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	06-27	MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	06-26	CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'	06-26	RE
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia	06-26	RE
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained	06-25	MT
Declaration of Voting Results by Regeneron Pharmaceuticals, Inc	06-20	CI
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	06-18	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing	06-17	MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050	06-17	MT
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response	06-17	MT

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,082 USD

Average target price

1,063 USD

Spread / Average Target

-1.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+23.21%	117B
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+24.16%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.06%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs

Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Regeneron Pharmaceuticals : Exec Says Its Antibody Cocktail Therapy For COVID-19 Will Likely Help Against Variants Of The Virus - J.P.Morgan Conf

Latest news about Regeneron Pharmaceuticals, Inc.

Chart Regeneron Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Ratings for Regeneron Pharmaceuticals, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs